Tabula Rasa Healthcare Inc. (NASDAQ:TRHC) had its price target increased by stock analysts at Chardan Capital from $19.50 to $21.00 in a research note issued to investors on Tuesday, Marketbeat.com reports. The brokerage presently has a “buy” rating on the stock. Chardan Capital’s price target suggests a potential upside of 23.60% from the stock’s previous close.

Several other brokerages have also issued reports on TRHC. Stifel Nicolaus reaffirmed a “buy” rating and set a $16.00 target price on shares of Tabula Rasa Healthcare in a research report on Friday, July 14th. Zacks Investment Research raised Tabula Rasa Healthcare from a “sell” rating to a “hold” rating in a report on Tuesday, May 16th. Finally, UBS AG reissued a “buy” rating and issued a $17.00 price objective (down previously from $18.00) on shares of Tabula Rasa Healthcare in a report on Thursday, May 25th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. The company has an average rating of “Buy” and an average price target of $17.83.

Tabula Rasa Healthcare (NASDAQ TRHC) opened at 16.99 on Tuesday. The company’s market capitalization is $292.53 million. Tabula Rasa Healthcare has a 52-week low of $10.39 and a 52-week high of $18.25. The firm’s 50-day moving average is $14.94 and its 200-day moving average is $14.07.

Tabula Rasa Healthcare (NASDAQ:TRHC) last announced its earnings results on Monday, August 7th. The company reported $0.06 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.06. Tabula Rasa Healthcare had a negative return on equity of 12.06% and a negative net margin of 10.27%. The firm had revenue of $29.70 million during the quarter, compared to analyst estimates of $27.84 million. The firm’s quarterly revenue was up 32.6% on a year-over-year basis. On average, equities research analysts forecast that Tabula Rasa Healthcare will post $0.41 EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Tabula Rasa Healthcare Inc. (TRHC) Price Target Raised to $21.00 at Chardan Capital” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright legislation. The correct version of this report can be viewed at https://www.thecerbatgem.com/2017/08/10/tabula-rasa-healthcare-inc-trhc-price-target-raised-to-21-00-at-chardan-capital.html.

In related news, Director Gordon Tunstall sold 22,759 shares of Tabula Rasa Healthcare stock in a transaction dated Monday, June 12th. The stock was sold at an average price of $13.76, for a total value of $313,163.84. Following the completion of the sale, the director now owns 5,565 shares of the company’s stock, valued at approximately $76,574.40. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Glen R. Bressner acquired 7,500 shares of the firm’s stock in a transaction that occurred on Thursday, May 18th. The stock was purchased at an average cost of $11.96 per share, with a total value of $89,700.00. Following the acquisition, the director now owns 18,256 shares in the company, valued at approximately $218,341.76. The disclosure for this purchase can be found here. In the last three months, insiders sold 46,759 shares of company stock valued at $634,444. 45.80% of the stock is currently owned by insiders.

A number of large investors have recently made changes to their positions in TRHC. TIAA CREF Investment Management LLC raised its stake in shares of Tabula Rasa Healthcare by 108.5% in the first quarter. TIAA CREF Investment Management LLC now owns 8,131 shares of the company’s stock valued at $110,000 after buying an additional 4,232 shares during the period. Bank of New York Mellon Corp purchased a new stake in shares of Tabula Rasa Healthcare during the first quarter valued at $178,000. Cadence Capital Management LLC purchased a new stake in shares of Tabula Rasa Healthcare during the second quarter valued at $210,000. Russell Investments Group Ltd. raised its stake in shares of Tabula Rasa Healthcare by 58.1% in the second quarter. Russell Investments Group Ltd. now owns 94,089 shares of the company’s stock valued at $1,415,000 after buying an additional 34,565 shares during the period. Finally, Boston Partners raised its stake in shares of Tabula Rasa Healthcare by 17.1% in the second quarter. Boston Partners now owns 235,180 shares of the company’s stock valued at $3,540,000 after buying an additional 34,360 shares during the period. 24.99% of the stock is owned by institutional investors.

Tabula Rasa Healthcare Company Profile

Tabula Rasa HealthCare, Inc (Tabula Rasa), formerly CareKinesis, Inc, is a provider of patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations and manage risk. The Company delivers its solutions through a suite of technology-enabled products and services for medication risk management, which includes bundled prescription fulfillment and adherence packaging services for client populations with complex prescription needs.

Analyst Recommendations for Tabula Rasa Healthcare (NASDAQ:TRHC)

Receive News & Stock Ratings for Tabula Rasa Healthcare Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa Healthcare Inc. and related stocks with our FREE daily email newsletter.